close

AGENDA

UPCOMING EVENTS

All seminars take place usually each Tuesday at 11 am at 11:00 AM in the meeting room “Philippe Jeanteur “.

2 July 2026
  • Robert S. ILLINGWORTH - Institute for Regeneration and Repair, University of Edinburgh

    2 July 2026  10 h 30 min - 12 h 00 min
    Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, France


    Title : Passive Yet Essential, Polycomb Repression in Development and Disease

    Contact : carla.heredia@igmm.cnrs.fr

    Voir plus de détails

  • Prof. Alan TALEVI (Universidad Nacional de La Plata, La Plata, Argentina)

    2 July 2026  11 h 00 min - 12 h 00 min
    Marcel Dorée Seminar Room

    CRBM External Seminar
    “Machine Learning and Structure-Based Approaches for the Discovery of Biomarkers and Bioactive Compounds”
    Contact: andrey.kajava@crbm.cnrs.fr

    Voir plus de détails

3 July 2026
  • Vincent Loubière - IGH Montpellier

    3 July 2026  13 h 00 min - 14 h 00 min
    Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, France

    Title : “Epigenetic and cis-regulatory determinants of tumorigenesis"
    Contact : nadine.laguette@igmm.cnrs.fr

    Voir plus de détails

17 July 2026
  • Seminar : Alexander Waclawiczek, DKFZ, Heidelberg, Germany

    17 July 2026  11 h 00 min - 13 h 00 min
    Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, France

    Title: The Genotype–Phenotype Relationship as Mediator of Therapy Resistance in Acute Myeloid Leukemia 

    Abstract:
    Acute myeloid leukemia (AML) is characterized by extensive genetic and phenotypic heterogeneity. Leukemic stem cells (LSCs) are a self-renewing subpopulation of AML cells that sustains disease initiation, progression, and relapse. By translating the underlying pathogenic genotype into a malignant cellular phenotype and generating the progeny that constitute the bulk of the leukemia, LSCs lie at the interface between genotype and phenotype. Over the past decade, both genetic alterations and cellular phenotypes have emerged as important determinants of therapeutic response in AML. Deciphering how these features interact within LSCs may therefore provide new insights into treatment response, disease persistence, and the development of therapy resistance.

    Contact : guillaume.bossis@igmm.cnrs.fr

    Voir plus de détails